Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer

International Journal of Urology

Volumn 10, Issue 7, 2003, Pages 387-391

  Odrazka, Karel ^a   Vaculikova, Miloslava ^a   Petera, Jiri ^a   Moravek, Petr ^a   Prosvic, Petr ^a   Zoul, Zdenek ^a   Rydel, Lubos ^a   Brodak, Milos ^a   Veselsky, Zbynek ^a   Louda, Miroslav ^a   Simakova, Eva ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Dexamethasone; Epirubicin; Etoposide; Hormone refractory prostate cancer

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; CORTICOSTEROID; DEXAMETHASONE; EPIRUBICIN; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; MEDROXYPROGESTERONE ACETATE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GENERAL CONDITION IMPROVEMENT; HEART DISEASE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; MALE; MEASUREMENT; NAUSEA; PRIORITY JOURNAL; PROSTATE CANCER; REFRACTORY PERIOD; SCORING SYSTEM; SOFT TISSUE METASTASIS; STANDARD; THROMBOCYTOPENIA; TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANALGESICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; ETOPOSIDE; HORMONE ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PAIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0042704775     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2003.00647.x     Document Type: Article

References (24)

1. Culine S, Droz JP. Chemotherapy in advanced androgen-independent prostate cancer 1990-99: a decade of progress? Ann. Oncol. 2000; 11: 1523-30.
2. Heidenreich A, von Knobloch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur. Urol. 2001; 39: 121-30.
3. Hudes G, Einhorn L, Ross E et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J. Clin. Oncol. 1999; 17: 3160-6.
4. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J. Clin. Oncol. 1999; 17: 2506-13.
5. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996; 14: 1756-64.
6. Dimopoulos MA, Panopoulos C, Bamia C et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997; 50: 754-8.
7. Pienta KJ, Redman BG, Bandekar R et al. A phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer. Urology 1997; 50: 401-6.
8. Sumiyoshi Y, Hashine K, Nakatsuzi H, Yamashita Y, Karashima T. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer. Int. J. Urol. 2000; 7: 243-7.
9. Culine S, Kattan J, Zanetta S, Théodore C, Fizazi K, Droz JP. Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Am. J. Clin. Oncol. 1998; 21: 470-4.
10. Ellerhorst JA, Tu SM, Amato RJ et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin. Cancer Res. 1997; 3: 2371-6.
11. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate-specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995; 76: 96-100.
12. Morioka M, Kobayashi T, Furukawa Y et al. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol. Int. 2002; 68: 10-5.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457-81.
15. Arduino LJ, Mellinger GT. Clinical trial of busulfan (NSC-750) in advanced carcinoma of prostate. Cancer Chemother. Rep. 1967; 51: 295-303.
16. Pavone Macaluso M, Caramia G, Vecchioni M. Antiblastic chemotherapy in the treatment of cancer of the prostate. J. Urol. Nephrol. (Paris) 1972; 78: 621-34.
17. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71 (Suppl. 3): 1098-109.
18. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 1993; 11: 607-15.
19. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J. Clin. Oncol. 2001; 19: 2509-16.
20. Dowling AJ, Czaykowski PM, Krahn MD, Moore MJ, Tannock IF. Prostate-specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer. prognostic factors and generalizability of a multicenter trial to clinical practice. J. Urol. 2000; 163: 1481-5.
21. Small EJ, Srinivas S, Egan B, McMillan A, Rearden TP. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J. Clin. Oncol. 1996; 14: 1617-25.
22. Huan SD, Stewart DJ, Aitken SE, Segal R, Yau JC. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am. J. Clin. Oncol. 1999; 22: 471-4.
23. Veronesi A, Re GL, Foladore S et al. Multidrug chemotherapy in the treatment of non-elderly patients with hormone-refractory prostatic carcinoma. A phase II study. North-Eastern Italian Oncology Group (GOC-CNE). Eur. Urol. 1996; 29: 434-8.
24. Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94: 1457-65.